Tilray Brands, Inc. (TLRY) closed at $1.28 in the latest trading session, marking a -1.54% move from the prior day.
One of the starkest examples of the marijuana industry's struggles is the trajectory of one of its flagship stocks, Tilray (TLRY -2.98%).
Marijuana legalization doesn't appear to be on the horizon anytime soon. And as a result of the lack of excitement in the industry, many cannabis stocks are struggling, badly.
In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $1.37, denoting a +0.74% change from the preceding trading day.
Tilray Brands (TLRY -4.22%) shares still aren't delivering on what investors may have hoped for, falling by 25% during the past 12 months. But, with a few catalysts in play, and with more operational improvements, anything is possible, and hope springs eternal.
The outcome of elections can shape policies and decisions for years to come, and it's no exception in the U.S. Following Donald Trump's election as the 47th president of the United States and Republicans gaining control of the Senate and the House of Representatives, some companies and industries could potentially benefit from the change in administration at the national level. Others, not so much.
After TLRY hits a 52-week low, we assess whether the current level warrants an opportunity to accumulate shares, hold positions or book profits.
Tilray Brands stock resumed the downward trend and crashed to its all-time low after suffering a major setback in the United States. TLRY shares plunged to a low of $1.36 on Monday, bringing the year-to-date losses to 36%.
In a fireside chat with senior analyst Pablo Zuanic on October 23, 2024, Tilray Brands TLRY CEO Irwin Simon shared insights into the company's growth strategies, highlighting profitability, U.S. market entry and the expansion of their cannabis and beverage businesses. Simon also addressed the recent quarterly performance and challenges the company faces in both domestic and international markets.
Tilray Brands (TLRY) stock price has gone nowhere in the past few months. It has found a strong support level at $1.61, where it has failed to move below since November last year.
Tilray is beaten down, but that alone doesn't make it cheap.
Tilray's Q1 revenue missed estimates by $21 million, showing 13% year-over-year growth driven by beverage acquisitions, while cannabis revenue declined nearly 13%. The company reported a larger GAAP operating loss, but improved GAAP net loss, and a 13% decline in adjusted EBITDA, with significant cash burn and shareholder dilution. Tilray's valuation discount to Canopy Growth has narrowed, with analysts still very positive but cutting their price targets over time.